Clinical Research Directory

Inclusion Criteria: * ≥ 18 and ≤ 85 years old * Able to provide informed consent * AICD implanted for primary prophylaxis against sudden cardiac death * AICD implanted for secondary prophylaxis against spontaneous or inducible sustained VT without any reversible causes * CAD with prior myocardial infarction (\>60 days prior to enrollment) * AICD or ECG documentation of ventricular arrhythmia responsible for appropriate AICD therapy (\> 3 ATP or ≥ 1 appropriate Shock) Exclusion Criteria: * Contraindication or allergy to contrast media, routine procedural medications or catheter materials * Contraindication to an interventional procedure * Current or previous (within 3 months) antiarrhythmic therapy * Absolute contraindication to amiodarone or other AAD * New York Heart Association (NYHA) functional class IV * Stroke within the past 90 days * Unstable angina * Hypertrophic cardiomyopathy, Non-ischemic dilated cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia, Brugada Syndrome, Catecholamine sensitive polymorphic VT or long QT syndrome * Subjects with active ischemia that are eligible for revascularization * Life expectancy less than 6 months * Incessant or multiple episodes of VT requiring immediate therapy with medications or ablation * Untreated hypothyroidism or hyperthyroidism. Subjects who are euthyroid on thyroid hormone replacement therapy are acceptable. * Current enrollment in another investigational drug or device study. * Presence of any other condition that the investigator feels would be problematic or would restrict or limit the participation of the Subject for the entire study period. * Absolute contra-indication to the use of heparin and or warfarin. * Documented intra-atrial thrombus, ventricular thrombus (\< 6 months after detection of thrombus), tumor, or another abnormality, which precludes catheter introduction. * Previous VT ablation * Are pregnant.